Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(19):1420-1422; doi:10.1093/jnci/90.19.1420
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

How to Slice It? Tissue Technologies Vie for Potentially Lucrative Market

The race to isolate single cells for genetic and molecular analysis has grown contentious, with a rift as broad as the Atlantic and as thin as a laser beam separating the three competitors. A technology developed at the National Institutes of Health, called laser capture microdissection (see News, Dec. 4, 1996), dominates the small, but growing, United States market. However, two other companies -- one in Germany and the other also in the United States -- are actively criticizing the NIH system and proffering their own as superior.

So far, the stakes are relatively small. The companies each report worldwide sales of only 40 to 100 instruments, which wed lasers to microscopes and zap small groups of cells into test tubes. But within a decade, the expectation is that these instruments will work their way out of the . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?